H
Henry Milgrom
Researcher at Anschutz Medical Campus
Publications - 91
Citations - 4820
Henry Milgrom is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Asthma & Omalizumab. The author has an hindex of 31, co-authored 91 publications receiving 4601 citations. Previous affiliations of Henry Milgrom include California State University, Long Beach & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Noncompliance and treatment failure in children with asthma
TL;DR: Electronic monitoring demonstrated much lower adherence to prescribed therapy than was reported by patients on diary cards, and low rates of compliance with prescribed inhaled corticosteroids were associated with exacerbation of disease.
Journal ArticleDOI
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Henry Milgrom,William E. Berger,Anjuli Nayak,Niroo Gupta,Stephen Pollard,Margaret McAlary,Angel Fowler Taylor,Patricia Rohane +7 more
TL;DR: Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids, and cause a down-regulation of FcepsilonRI receptors on basophils.
Journal ArticleDOI
Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT.
Bruce G. Bender,Frederick S. Wamboldt,Shannon L. O'Connor,Cynthia S. Rand,Stanley J. Szefler,Henry Milgrom,Marianne Z. Wamboldt +6 more
TL;DR: Electronic adherence monitoring was significantly more accurate than self-report or canister weight measures and was an essential prerequisite to increasing understanding of the treatment, setting, and patient factors that influence adherence and to the consequent design of effective intervention strategies.
Journal ArticleDOI
Recombinant interferon gamma therapy for atopic dermatitis.
Jon M. Hanifin,Lynda C. Schneider,Donald Y.M. Leung,Charles N. Ellis,Howard S. Jaffe,Allen E. Izu,Louis R. Bucalo,Sue E. Hirabayashi,Susan J. Tofte,Graciela Cantu-Gonzales,Henry Milgrom,Mark Boguniewicz,Kevin D. Cooper +12 more
TL;DR: This study demonstrated that rIFN-gamma given by daily subcutaneous injection over a 12-week period was safe, well accepted, and effective in reducing inflammation, clinical symptoms, and eosinophilia in severe atopic dermatitis.
Journal ArticleDOI
Nonadherence in asthmatic patients : is there a solution to the problem?
TL;DR: Improved adherence will lead to improved disease control, but only if medical care systems encourage and support the allocation of sufficient resources to allow barriers to self-management to be discussed and solutions negotiated.